Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01553370
Other study ID # BUCT-11-221
Secondary ID
Status Not yet recruiting
Phase N/A
First received March 12, 2012
Last updated March 13, 2012
Start date April 2012
Est. completion date February 2013

Study information

Verified date March 2012
Source Brock University
Contact Brian D Roy, PhD
Phone 905-688-5550
Email broy@brocku.ca
Is FDA regulated No
Health authority Canada: Brock University Bioscience Research Ethics BoardCanada: Hamilton Health Sciences/McMaster University Faculty of Health Sciences Research Ethics Board
Study type Interventional

Clinical Trial Summary

Maintaining a healthy body weight is a major challenge for the majority of Canadians. A lifestyle strategy that promotes maintenance of a healthy body weight and, perhaps most importantly, can be incorporated into daily life with relative ease is essential. This study will determine if an effective strategy includes increased physical activity in conjunction with higher intakes of dairy products immediately following exercise. Fifty-six overweight adult males who do not regularly exercise will be assigned to one of four groups for 12 weeks. All groups will preform 12 weeks of exercise training (1 hour of cycling per day, 5 times per week). Two groups will consume supplemental low fat milk (3 servings per day) with one these groups consuming it immediately after exercise while the other will consume it either well before or long after the exercise session. The other two groups will consume a carbohydrate drink that has the same amount of energy as the low fat milk, with one of these groups consuming the drink right after exercise and the other another group will consume it either well before or long after the exercise session. Markers of health status including body weight, muscle mass, and bone mass will be measured at the start and after the 12- week intervention. The investigators anticipate that providing the low fat milk immediately after exercise will result in the most favorable changes in health outcomes, and provide a realistic lifestyle intervention for overweight individuals to attain a healthy body weight, and by doing so, optimize their ability to prevent chronic disease.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 54
Est. completion date February 2013
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 28 Years
Eligibility Inclusion Criteria:

- BMI greater or equal to 25

- healthy

Exclusion Criteria:

- any chronic cardiovascular condition or metabolic condition

- kidney disease

- gastro-intestinal disease

- milk or dairy protein allergies

- lactose intolerance

- chronic lung conditions

- any condition that could potentially prevent participant from performing exercise

- allergy to local anaesthetics

- cumulative x-ray exposure and cumulative muscle biopsies

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Increased Dairy Intake
3 additional servings of low fat dairy will be consumed
Supplemental carbohydrate
Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.

Locations

Country Name City State
Canada Brock University St. Catharines Ontario

Sponsors (1)

Lead Sponsor Collaborator
Brock University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body composition 12 weeks No
Primary Bone mineral density 12 weeks No
Primary VO2 peak 12 weeks No
Secondary mitochondrial enzyme activity 12 weeks No
Secondary muscle oxidative stress 12 weeks No
Secondary muscle capillary density 12 weeks No
Secondary blood lipids 12 weeks No
Secondary blood inflammatory markers 12 weeks No
Secondary blood markers of bone turnover 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4